Zhang, Di
Wang, Guoxun
Yu, Xueliang
Wei, Tuo http://orcid.org/0000-0002-2823-9721
Farbiak, Lukas http://orcid.org/0000-0003-4107-1676
Johnson, Lindsay T. http://orcid.org/0000-0002-4563-5486
Taylor, Alan Mark
Xu, Jiazhu
Hong, Yi http://orcid.org/0000-0002-5846-2596
Zhu, Hao
Siegwart, Daniel J. http://orcid.org/0000-0003-3823-1931
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP160157, RP190251)
Pharmaceutical Research and Manufacturers of America Foundation (Predoctoral Fellowship in Drug Delivery)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA251928, 5P30CA142543, R01 CA269787-01)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01 EB025192-01A1)
American Cancer Society (RSG-17-012-01)
Welch Foundation (I-1855)
Cystic Fibrosis Foundation (SIEGWA18XX0)
Article History
Received: 15 June 2020
Accepted: 21 March 2022
First Online: 12 May 2022
Competing interests
: D.J.S. is a co-founder and consultant of ReCode Therapeutics, which has licensed intellectual property from UT Southwestern. H.Z. has a sponsored research agreement with Alnylam Pharmaceuticals, consults for Flagship Pioneering and serves on the Scientific Advisory Board of Ubiquitix. H.Z.’s interests are not directly related to the contents of this paper. The other authors declare no competing interests.